EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A PK ‐Driven Quantitative Systems Pharmacology Model Predicts Cytokine Release Syndrome Severity Across T Cell‐Activating Therapies via a Locked Cytokine Amplification Network

Hajar Besbassi iD

CPT: Pharmacometrics & Systems Pharmacology · 2026-11 · 15 (11)

DOI: 10.1002/psp4.70376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 13.11.2026. Verfasst von Hajar Besbassi. Beteiligte Einrichtung: Antwerp Centre for Translational Immunology and Virology (ACTIV), University of Antwerp, Antwerp, Belgium. Hauptthemen laut MEDLINE: Cytokine Release Syndrome, T-Lymphocytes, Cytokines, Models, Biological. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cytokine release syndrome (CRS) is a major dose‐limiting toxicity of T cell‐engaging immunotherapies. Existing CRS models are drug‐class‐specific; here we show that a single locked cytokine network captures CRS severity across mechanistically distinct drug classes, changing only drug‐specific upstream activation parameters. We developed a PK‐driven quantitative systems pharmacology (QSP) model linking drug exposure, T cell activation dynamics, and a macrophage‐amplified cytokine network to clinical CRS severity. The 17‐parameter downstream amplification network with macrophage‐gated STAT3 positive feedback was calibrated on blinatumomab, structurally refined using TGN1412 as a transparently disclosed development case, then locked and tested blind on OKT3. The locked network reproduced the clinically observed CRS severity ordering across all three antibody‐based T cell engager classes (bispecific, CD28 superagonist, and anti‐CD3 with activation‐induced cell death) without re‐fitting any shared parameter. The OKT3 blind prediction passed eight qualitative plausibility checks, and its peak TNF‐ fell within values measured in patients. Tocilizumab rescue simulation reproduced five clinically validated phenomena. A mechanistic parameter swap reversing the T cell exhaustion rate between OKT3 and TGN1412 reversed CRS severity in the expected direction. Local robustness analysis (926 of 5000 parameter sets accepted, 18.5%) and a 2D stability map over the two threshold‐setting parameters (0 of 900 wrong‐order combinations) confirmed that the cross‐drug severity ordering is a property of a feasible parameter region rather than a single tuned point. The locked model predicted three distinct dose–response shapes without re‐fitting. Findings should be interpreted as a mechanistic proof‐of‐concept; prospective clinical validation remains pending.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytokine Release SyndromeT-LymphocytesCytokinesModels, BiologicalHumansAntibodies, Monoclonal, HumanizedAntibodies, BispecificLymphocyte ActivationPiperidinesMuromonab-CD3Severity of Illness IndexNetwork Pharmacology

Stichwörter der Autor:innen

PharmacometricsT cell engagerscytokine release syndromemodel‐informed drug developmentquantitative systems pharmacology

Substanzen

Antibodies, Monoclonal, HumanizedCytokinesTGN-1412Antibodies, BispecificPiperidinesMuromonab-CD3

Autor:innen und Institutionen

  • Antwerp Centre for Translational Immunology and Virology (ACTIV), University of Antwerp, Antwerp, Belgium.
  • Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID), University of Antwerp, Antwerp, Belgium.
  • Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium.

ORCID-Profile: Hajar Besbassi

Zitieren

APA

Besbassi, H. (2026). A PK ‐Driven Quantitative Systems Pharmacology Model Predicts Cytokine Release Syndrome Severity Across T Cell‐Activating Therapies via a Locked Cytokine Amplification Network. CPT: Pharmacometrics & Systems Pharmacology, 15(11). https://doi.org/10.1002/psp4.70376

Vancouver

Besbassi H. A PK ‐Driven Quantitative Systems Pharmacology Model Predicts Cytokine Release Syndrome Severity Across T Cell‐Activating Therapies via a Locked Cytokine Amplification Network. CPT: Pharmacometrics & Systems Pharmacology. 2026;15(11). doi:10.1002/psp4.70376

BibTeX
@article{Besbassi2026,
  author = {Besbassi, Hajar},
  title = {A PK ‐Driven Quantitative Systems Pharmacology Model Predicts Cytokine Release Syndrome Severity Across T Cell‐Activating Therapies via a Locked Cytokine Amplification Network},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.1002/psp4.70376}
}
Kostenlos starten →